9th MASH Drug Development Summit

As part of a packed lineup of scientific meetings this season, Nordic Bioscience’s liver team is heading to the MASH Drug Development Summit, taking place September 29 – October 1, 2025, in Boston, MA.

With the field of metabolic dysfunction-associated steatohepatitis (MASH) rapidly evolving, this summit offers a focused platform to engage in cutting-edge discussions on therapeutic advancements, trial design, and biomarker strategy. Nordic Bioscience will contribute to the conversation by highlighting the use of FIB-NIT™, a translational biomarker panel developed to monitor both fibrogenesis and fibrolysis in real time.

FIB-NIT™ enables dynamic tracking of liver fibrosis activity, supporting better-informed clinical decisions and improving the design and evaluation of antifibrotic therapies. It’s already playing a role in advancing MASH research by helping to stratify patients and assess treatment response non-invasively. Learn more about FIB-NIT™ here.

We look forward to connecting with fellow experts in liver disease research and continuing to advance biomarker-driven innovation.